Abstract 28
The species B human adenoviruses (short Ad) infect cells upon attaching to CD46 or 29 desmoglein-2 (DSG-2) by one or several of their twelve fiber knob trimers (FK). To 30 test whether DSG-2 and CD46 simultaneously serve as virus receptors for Ad3, we 31 performed individual and combined CD46/DSG-2 loss-of-function studies in human 32 lung A549 and 16HBE14o cells. Our results suggest that in these cells, DSG-2 33 functions as major attachment receptor for Ad3, whereas CD46 exerts a minor 34 contribution to virus attachment and uptake in the range of ~ 10%. However, in other 35 cells the role of CD46 may be more pronounced depending on, e.g., the expression 36 levels of the receptors. To test if avidity allows Ad3/7 to use CD46 as receptor, we 37 antibodies were combined, we noticed a significant additive inhibition resulting in 264 70% inhibition of Ad3 binding. In comparison, the high concentrations of CD46 265 antibody reduced Ad35 binding by 93 and 98%, but the DSG-2 antibody mix had no 266 significant effects (Fig. 1B) . These results are consistent with the notion that Ad35 267 uses CD46 but not DSG-2 as an attachment receptor (13, 67). 268
We next performed siRNA-mediated knock down of CD46, DSG-2 and both 269 receptors together, and analyzed these cells for virus binding and transduction. 270
Initial tests for optimizing siRNA concentrations confirmed that best CD46 down-271 regulation was obtained using a single CD46-specific siRNA at 5 nM, whereas a pool 272 of four DSG-2-specific siRNAs each at 5 nM was optimal for DSG-2 protein 273 downregualtion when measured by cytofluorometric analyses (15, 70). In five 274 independent experiments, siRNA-mediated reduction of CD46 was in the range of 74 275 to 88% with a mean of 82%, when using the CD46-specific siRNA alone, and 67 to 276 86% with a mean of 77%, when using the CD46-specific siRNA in combination with 277 DSG-2-specific siRNAs (see Fig. 1C for a representative experiment) . Similarly, 278
siRNA-mediated reduction of DSG-2 was in the range of 68 to 80% with a mean of 279 73%, when using the DSG-2 siRNAs alone, and 63 to 82% with a mean of 71%, 280 when using the DSG-2 siRNAs in combination with the CD46 siRNA. When binding 281 of atto-488 labeled Ad3 to these cells was analyzed, we noticed that in CD46 siRNA-282 only-cells binding was reduced by 28% in the experiment shown in Fig. 1D , whereas 283 binding of Ad3 to DSG-2 siRNA-only-cells was reduced by 66%. Similar as for the 284 antibody blocking experiments, combination of both siRNAs additively reduced Ad3 285 binding to 77%. Of note, the additive Ad3 binding reduction was not paralleled by a 286 reduction of the DSG-2 expression level in the siRNA combination cells, indicating 287 specificity for CD46. The range of reduction varied from 3 to 23%, with a mean of 288 11%. As for the antibody inhibition experiment, Ad35 attachment was mainly 289 affected by CD46 but not DSG-2 interference, resulting in 76 and 77% binding 290 reduction for CD46-only siRNA and CD46 plus DSG-2 siRNAs, respectively. 291
Attachment of the CAR-binding Ad2 was not affected in these cells, demonstrating 292 the specificity of the observed virus binding reduction for Ad3/35. 293
We then used the four different siRNA cells to analyze transduction by Ad5, Ad3 and 294 Ad35-eGFP reporter viruses. CD46 interference gave no decrease in eGFP 295 expression for Ad3/5 (Fig. 1E) . However, Ad3-eGFP-mediated expression was 296 reduced by 71% in DSG-2 siRNA-treated cells and by 82% in DSG-2 plus CD46 297 siRNA combination cells, revealing a small additive effect of 11% (Fig. 1E) . The 298 additive reduction in Ad3 infection by siRNA combination cells was reproducibly 299 significant, and varied from 11 to 17%, with a mean of 13% in 4 of 5 experiments. It 300 should be noted here that CD46 down-regulation had a very small effect on the 301 transduction by Ad35-eGFP. We therefore repeated this experiment using a chimeric 302
Ad5 containing the fiber knob and shaft from Ad35 (Ad5-eGFP-FK35), and found a 303 60% reduction of transgene expression upon CD46 siRNA silencing (data not 304 shown). This was similar to data from others using a similar fiber chimeric vector 305 (15). As suggested earlier, a possible explanation for these observations includes 306 that fiber-knob swapped vectors have altered intracellular trafficking or stability (63). 307
Using the same approach, we also tested human 16HBE14o bronchial epithelial 308 cells, which are a commonly used model for respiratory epithelial cell infections (17, 309 35). These cells revealed about 2-fold lower CD46 (sFig. 1C) and 3-4-fold lower 310 DSG-2 (sFig. 1D) expression, when compared to A549 cells. siRNA-mediated 311 reduction of CD46 and DSG-2 was in average 89 and 91%, respectively, when using 312 the single-specific siRNA alone or in combination (Fig. 1F) . Binding of atto-488 313 labeled Ad3 in CD46 was reduced by 20 and 85% in CD46 and DSG-2 siRNA-only-314 cells, respectively, and combination of both siRNAs additively reduced Ad3 binding to 315 95% (Fig. 1G ). When using the four different siRNAs cells to analyze transduction by 316 eGFP reporter viruses, Ad3-eGFP-mediated expression was reduced by 48% in 317 DSG-2 siRNA-treated cells and by 76% in DSG-2 plus CD46 siRNA combination 318 cells, revealing an additive effect of 28% (Fig. 1H) . 319
Taken together, our results suggest that A549 and 16HBE14o cells expressing both 320 DSG-2 and CD46, DSG-2 functions as major attachment receptor for Ad3, whereas 321 CD46 exerts an accessory role for binding and uptake. In other human cells, 322 however, the CD46 contribution may be more pronounced depending, e.g., on the 323 Fig. 2B) ) and they did not stain with a DSG-2 338 antibody (data not shown), suggesting that they lack expression of DSG-2 or that 339 hamster DSG-2 is not able to bind human Ad3. The highest levels of CD46 were 340 measured in CHO-CD46#2 cells with an arbitrary mean fluorescence intensity (MFI) 341 of 161, followed by CHO-CD46#1 (MFI of 45), and CHO-CD46#6 (MFI of 33) 342 (sFig. 1A). All three CHO clones were derived from CHO-15B6 cells. Additional 343 CHO-CD46#RC cells, which were derived from CHO-K1 cells (4) and expressed 344 similar CD46 levels as CHO-CD46#1 were included as controls in the transduction 345 study. These cells gave similar data to CHO-CD46#1 and are not shown here. We 346 noticed, however, that the CD46 stably transfected cells had broader expression 347 ranges than for example human lung carcinoma A549 cells, which had an MFI of 74. 348
We therefore used the stable CD46 expressing CHO cells at low passage numbers 349 to ensure comparable expression levels. Cells were incubated with 1,000 vp of infection of CHO-CD46#6, #1, #2 and A549 required 27, 16, 4.2 and 2.7-fold higher 377 vp input to obtain the MFI value of 100, respectively. For Ad7, these numbers 378 amounted to 9.5, 7.3, 1.57 and 1.1-fold. In contrast, Ad11 had a similar transduction 379 efficacy as Ad35. Of note, when using Ad5-eGFP in these cells, transduction levels 380 were within a factor of 2 for the different CD46-expressing clones including the 381
parental CHO cells. 382
We also tested whether human melanoma M010119 cells with low CD46 expression 383 (MFI of 17.8) (sFig. 1E) were increasingly transduced with Ad-eGFP vectors by 384 increasing CD46 levels. Stable transfection of these cells (M010119-eGFP-CD46#8) 385 resulted in about 9-fold higher CD46 expression levels (MFI of 155), compared to the 386 parental cells. In this case, an N-terminal eGFP-tagged CD46 BC1 isoform was 387 used, where the endogenous signal peptide was replaced by the CAR signal peptide, 388 followed by the eGFP sequence and the sequence of the mature CD46 BC1 isoform. 389
Of note, the receptor function of the eGFP-tagged CD46 form was retained for all 390 four species B serotypes tested in M010119-eGFP-CD46#8 cells (Fig. 2C, Table 2 ). 391
When using 1,000 vp/cell, M010119-eGFP-CD46#8 cells with the 9-fold higher CD46 392 level revealed 86, 26, 2.1 and 2.3-fold enhancements of reporter eGFP for 393 Ad3/7/11/35 mediated transduction, respectively, when compared to parental 394 M010119 cells. Determination of vp/cell ratios necessary to reach MFI value of 100, 395 revealed 127, 52, 3.1, and 2-fold enhancement of Ad3/7/11/35-mediated 396 transduction, respectively. Of note, both, the parental M010119 low-CD46 cells as 397 well as the M010119-eGFP-CD46#8 high-CD46 cells expressed no DSG-2, when 398 analyzed by cytofluorometric means (sFig. 1B, F), in contrast to A549 cells, which 399 expressed high levels of DSG-2. 400
In summary, ectopic expression of CD46 in rodent cells, or enhanced expression of 401 CD46 in human cells low in CD46 and negative for DSG-2 resulted in increased 402 transduction with Ad3/7/11/35 species B serotypes. Transduction efficacy of Ad3/7 403 correlated with CD46 density levels in these cells, whereas Ad11 reached a plateau 404 with the medium CHO-CD46#1 cells and Ad35 was largely independent of the CD46 405 levels. This is compatible with the notion that Ad3/7 exhibit a lower affinity for CD46 406 than Ad11/35, but can compensate the lower affinity by avidity binding. 407 408
Cross-linking of soluble CD46 enhances blocking of Ad3 and Ad7 infection of 409

CHO-CD46 and A549 cells. 410
We earlier documented that soluble CD46ex-huFc was at least 100-fold more potent 411 at blocking Ad11/35 binding to rodent cells expressing CD46, when compared to Ad3 412 and 7 (13). To further test the hypothesis that avidity allows Ad3/7 to use CD46 as a 413 functional receptor, we repeated the virus blocking assays with CD46ex-huFc, but 414 included this time cross-linked adapter proteins. We reasoned that antibody-415 mediated cross-linking of CD46ex-huFc could provide locally more binding sites per 416 molecule, mimicking the situation on the cell membrane where CD46 can diffuse 417 freely and form clusters following multivalent binding (1, 9). 418 When using 50, 500, and 5,000 ng/ml of CD46ex-huFc protein alone, only Ad11-419 eGFP or Ad35-eGFP mediated transgene expression were significantly reduced in 420 CHO-CD46#2 or A549 cells (Fig. 3A, B) . In contrast, CD46ex-huFc did not result in 421 significant reduction of Ad3/7 mediated transgene expression (sFig. 2A, B). 422
However, when we combined CD46ex-huFc protein at a concentration of 500 ng/ml 423 with 2-fold increasing amounts of cross-linking goat-anti human Fc antibody, 424 significant blocking was also achieved for both Ad3 and Ad7-mediated transgene 425 expression. Inhibition followed a precipitin-type curve reaching a plateau in the range 426 of 500, 1,000 or 2,000 ng/ml of goat anti-human Fc. Highest blocking for Ad3-eGFP 427 amounted to 65% in CHO-CD46#2 cells and 83% in A549 cells, and for Ad7-eGFP, 428 the highest blocking was 77% in both cell types. We conclude that CD46ex-huFc 429 multimerization leads to efficient blocking of Ad3/7. A similarly multimerized complex 430 consisting of CARex-huFc had no significant effects on Ad3/7 infection, but CARex-431 huFc inhibited Ad2/5 transduction (12, 38). We assured that FKs of Ad3/7/11/35 were 446 predominantly present in trimeric form (sFig. 3A, B). All five Ad FK proteins were 447 tested in a dose-dependent manner with the highest concentration of 5,000 ng/ml 448 diluted in a 5-fold dilution series to the lowest concentration of 8 ng/ml (Fig 4A, B and 449 Table 3 ). Specificity of this assay was confirmed by the finding that the species C 450
Ad5-FK only gave rise to inhibition of Ad5, but not for any of the species B serotypes. 451
Likewise, species B FKs only inhibited species B serotypes, but not Ad5-eGFP. 452
The cross-competition assays revealed differences in the capacity of the individual 453
FKs to compete with species B viruses. The Ad3/7-FKs on one side, and Ad11/35-454
FKs on the other side showed similar behavior, which, however, was different in the 455 two cell types tested. In CHO-CD46#2 cells, Ad3/7-FKs elicited at best weak 456 competition for corresponding and non-corresponding Ad3 and Ad7, and no effect on 457 non-corresponding Ad11 and Ad35. This is illustrated by the 40% inhibition of Ad3-458 eGFP transduction at the highest Ad3-FK concentration of 5,000 ng/ml, and a non-459 significant 7% inhibition for Ad7-eGFP transduction.
Ad3-FK concentrations 460 necessary for 50% inhibition (FK-50%) were larger than the highest concentration 461 available, and could thus not be calculated. Ad7-FK was more efficient than Ad3-FK, 462 and using 5,000 ng/ml, 86 and 81% of Ad3/7-mediated eGFP expression was 463 inhibited, respectively. FK-50% inhibition values for Ad7-FK were determined to be 464 169 and 2,690 ng/ml for Ad3/7-mediated transgene expression, respectively. In 465 contrast, Ad11/35-FKs led to efficient blocking of all B-type viruses in these cells. 466
Likewise, Ad35-FK blocking efficiency was in the range of 85 to 97% at 5,000 ng/ml, 467 and the corresponding FK-50% values were 5, 63, 14 and 26 ng/ml. (Fig. 4B, Table 3 ). With highest concentrations of Ad7-FK, blocking 472 efficiency of 95 and 87% was obtained for Ad3/7-mediated eGFP expression, 473 respectively, with FK-50% values of 17 and 31 ng/ml, respectively. However, as for 474 CHO-CD46#2 cells, Ad3/7-FKs revealed no effect on non-corresponding Ad11/35 in 475 A549 cells. Ad11-FK efficiently blocked all four species B serotypes, with FK-50% 476 inhibition values of 31, 87, 13, 13 ng/ml, whereas Ad35-FK was less efficient at 477 inhibiting Ad3 and 7, with FK-50% values of 470, and 4'459 ng/ml, respectively, but 478 very efficient at inhibiting Ad11 and 35, with FK-50% values of 33 and 5 ng/ml, 479
respectively. 480
In summary, blocking studies with Ad3/7-FKs revealed different effects for 481 corresponding viruses in CHO-CD46 cells or human A549 cells. In CHO-CD46 cells, 482 the observed low blocking efficiency confirms the low affinity of the Ad3/7 soluble FK 483 molecules to CD46. In contrast, the efficient blocking activity of Ad3/7-FK in A549 is 484 compatible with our findings that up to 90% of Ad3 binds with a presumable higher 485 affinity to DSG-2, whereas a minor fraction binds to CD46. 
CD46-SCRI-II, in agreement with earlier data for Ad7-FK (48). 501
In a reversed set-up of the SPR measurements we immobilized the extracellular 502 domain of CD46 fused to human Fc (CD46ex-huFc, see 60) to the flexible dextran 503 matrix of the sensor chip and used FKs as analytes. CD46ex-huFc is a disulfide-504 linked dimer, as suggested by native gel electrophoresis (sFig. 3C, and not shown). 505
We first tested if different concentrations of immobilized CD46ex-huFc would give 506 different binding responses for the FKs. Hereto, flow cell 2 (Fc2) of the CM5 sensor 507 chip was coated with high density of CD46ex-huFc (2,630 resonance units, RU), and 508 the control Fc1 with high density of CARex-huFc (3,431 RU). In a parallel set up, 509
Fc4 was coated with low surface density of CD46ex-huFc (345 RU), and Fc3 with low 510 density of CARex-huFc (278 RU). From the sensograms of Ad3/7/11/35-FK binding 511 to CD46ex-huFc we noticed that higher concentrations of soluble Ad3/7-FK (150 and 512 89 nM, respectively) were required to reach equilibrium binding at high CD46ex-huFc 513 density levels compared to Ad11/35-FK (18.75 nM) (Fig. 5A-D (Fig. 5E-H, sTable 1) . In addition, Ad3-FK binding was found to be 525 independent of the flow rate at the standard flow rate of 30 µl/min and an increased 526 flow rate of 55 µl/min, excluding the possibility that the binding reactions were 527 influenced by mass transfer effects (41). The values for the kinetic rate constants 528 were highly reproducible for the individual FKs, with low standard errors for the 529 association and dissociation constants (see Fig. 5E-H, sTable 1) . The kinetics and 530 binding data could be best fitted to a two-stage reaction model rather than 531
monophasic, or trivalent binding models (see equations in supplemental Methods). 532
Modeling of the measured association and dissociation rate constants and R values 533 was carried out based on global fittings for k a1 , k a2 , k d1 and k d2 , and local calculations 534 of R max , and % χ 2 /R max . All % χ 2 /R max values were below 5%. The average apparent 535 (Table 4) The data obtained in this study suggest that both, DSG-2 and CD46 can serve 549 simultaneously as Ad3 receptors and that avidity effects allow the low affinity CD46-550 binders Ad3/7-FK to attach to CD46 for infectious entry. Conspicuously, several Ad 551 serotypes have been reported to utilize more than one attachment receptor, which 552 could be part of an evolutionary strategy to increase viral fitness (76). For example, 553 the species D Ad9 with a very short fiber was found to allow fiber-independent 554 binding of the penton base directly to integrins, if integrins were present in sufficient 555 amounts (51). In integrin-low cells, the virus instead used CAR for productive 556 infection. Our findings that species B1 adenoviruses use avidity to bind to the CD46 557 receptor has important consequences for tropism and possibly evolution of the 558 species B1 viruses, where viral receptor-binding proteins are under selective 559 pressure and undergo constant variation to evade neutralization by antibodies (23, 560
47). High affinity binding could, for example, represent a dead-end in evolutionary 561
terms, as such viruses would be constrained to a single receptor. Weak affinity to a 562 receptor could be essential for gaining access to new attachment receptors. 563
564
Avidity captures low affinity interactions 565
Viruses use multiple binding strategies, characterized by a broad range of affinity 566 interactions when analyzed for single binding interaction sites (22, 73). Viruses with 567 low affinities include, e.g., influenza virus with millimolar affinity for sialic acid, and 568 micromolar affinities for rhinovirus attachment to intercellular adhesion molecule-1, 569 echovirus to decay-accelerating factor, or reovirus to junction adhesion molecule (2, 570 6, 28, 62). Biologically important binding of viruses to low affinity receptors occurs, 571 when virus particles expose multiple binding sites. This allows for avidity effects and 572 increases overall affinity. 573
Avidity is characterized by a synergistic (and not additive) combination of individual 574 bond affinities, which largely depends on the structure and geometry of the involved 575 molecules (36). For example, in the case of an IgG with a valency of two, avidity can 576 lead to a strong increase of overall affinity, when compared to corresponding 577 monovalent Fab fragments (see e.g., an early study from 16). Particularly strong 578 avidity effects were also reported for low affinity ErbB2-specific single chain variable 579 fragment antibodies, where the antibody fragment with the lowest affinity showed 580 highest avidity increase upon dimerization (44).
Viruses containing trimeric 581 attachment receptors, such as the reovirus sigma 1 protein or the long and short 582 fibers of bacteriophage T4, have been suggested to employ avidity mechanisms for 583 infection (as discussed in 33). Interestingly, binding of Ad3 to DSG-2 may engage 584 avidity mechanism, since multimerization of the trimeric Ad3 FK was required for 585 efficient binding to DSG-2 (69). 586 587
Avidity binding of adenoviruses to CD46 and CAR 588
Some studies considered Ad3/7 and also Ad14 to be CD46 non-binders due to low 589 With the FK neutralization experiments in CHO-CD46#2 expressing cells, we noticed 664 that Ad3/7-FKs did not efficiently compete against the binding of corresponding virus 665 particles, in contrast to Ad11/35-FKs, which efficiently blocked Ad3/7/11/35. This is 666 due to low affinity of Ad3/7-FK for CD46, since binding of the different species B Ads 667 is restricted to CD46 in these cells (13, 60). This conclusion was corroborated by the 668 findings that soluble CD46ex-huFc inefficiently inhibited binding of Ad3/7 to the cells, 669 in agreement with weak blocking efficiency of Ad3/7 by soluble CD46 (13, 67), and 670 also by soluble monovalent CD46 for MV infection (58). Ad3/7 inhibition was, 671 however, strongly enhanced by cross-linking the CD46ex-huFc protein (Fig. 3) , 672
suggesting that cross-linked CD46ex-huFc mimics the multiple interaction situation 673 when the virus contacts the cell surface. Similarly, CD46 cross-linking by genetically 674 fusing the CD46 ectodomain to the octamer oligomerization domain of C4b binding 675 protein resulted in a 2 log enhanced MV neutralizing activity in vitro and in vivo due to 676
enhanced virus binding (8). 677
These data suggest that the receptor density is of key importance not only for 678 interaction of CD46 with trimeric FK, but also the multivalent virus particle. Together 679 or alone, this gives rise to avidity effects, which allow Ad3/7 to infect cells expressing 680 sufficient levels of CD46 (13, 20, 60). The lack of Ad3/7 infection in CHO-CD46 cells 681
reported by other groups is most likely due to low CD46 expression levels, and assay 682 systems of low sensitivity or limited dynamic range (15, 18, 37, 57, 67). by ~ 10% compared to DSG-2 interference alone, showing that CD46 has a 688 significant role for infectious Ad3 entry in these cells. We suggest that in non-689 polarized A549, 16HBE14o or HeLa cells (70) expressing both receptors, DSG-2 690 functions as a major attachment receptor for Ad3. This could be due to a lower 691 affinity/avidity of Ad3 to CD46 compared to DSG-2, or to higher levels of DSG-2 692 compared to CD46. In other human cells the CD46 contribution may be more 693 pronounced depending on the expression levels of the receptors. This is supported 694 by our data from rodent CHO-CD46 and human M010119 melanoma cells lacking 695 DSG-2, where Ad3/7 uses CD46 as functional receptor. 696
For oncolytic therapies with HAdVs, it will be important to determine the DSG-2 697 expression levels among human cells and tissues in health and disease and put 698 these data in relation to CD46 expression. In particular, it is conceivable that DSG-2 699 and CD46 act independently as Ad3/7 receptors. For example in polarized cells, 700 DSG-2 is a component of the cell-cell adhesion structure of intercellular junctions 701 (26). CD46 is present on apical and basolateral surfaces (3, 59, 64). Apical CD46 702 may be an initial docking site for species B HAdVs, and lead to the activation of facilitates CD46 internalization by clathrin-mediated endocytosis or macropinocytosis, 718 followed by endosome lysis in the case of Ad3/35 and virus particle penetration from 719 endosomes to the cytosol (1, 9, 24). 720 721 
